Miebo (perfluorhexyloctane)
Research Synopsis
- Miebo (perfluorhexyloctane) has been approved by the FDA as an innovative ophthalmic solution designed specifically for treating dry eye disease (DED).* -
- Recent studies reveal that Miebo possesses a significant oxygen-carrying capacity, potentially aiding corneal health and healing in patients with dry eye conditions.* -
- Research demonstrates that Miebo effectively reduces the evaporation rate of tears, outperforming conventional artificial tears in laboratory tests.* -
- Clinical trials have indicated that Miebo significantly improves symptoms and signs of DED, with results visible within two weeks and lasting safety over a 12-month period.* -
- Miebo is derived from a unique water-free formula that can replace the natural lipid layer in the tear film, addressing an unmet need in reducing tear evaporation.* -
- The solution is preservative-free, enhancing patient safety and compliance due to its mild side effects.* -
- Long-term studies, such as the KALAHARI trial, found Miebo to be safe and well-tolerated, with sustained improvements in dry eye symptoms reported by participants.* -
- Multiple reviews highlight the escalating recognition of Miebo as a leading treatment option for DED, especially for patients experiencing symptoms linked to meibomian gland dysfunction (MGD).* -
- Overall, Miebo is positioned as a significant advancement in the management of dry eye disease, promising longer-lasting relief and addressing previously unmet treatment needs.*
Miebo (perfluorhexyloctane)
Oxygen-Carrying Capacity of Perfluorohexyloctane, a Novel Eye Drop for Dry Eye Disease.
London, UK
2 hours ago
1 Received
- The study investigates the oxygen content in perfluorohexyloctane (PFHO), an FDA-approved eye drop for treating dry eye disease, highlighting its efficacy and properties.* -
- Using fluorine-19 nuclear magnetic resonance spectroscopy, researchers measured T1 relaxation times and found that PFHO has a substantial level of oxygen compared to natural tears.* -
- Results suggest that PFHO does not hinder the oxygen needed for corneal health and may provide beneficial oxygen to aid healing in patients with dry eye.*
$100 - $150
Hourly Rate
In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease.
London, UK
2 hours ago
1 Received
- PFHO (perfluorohexyloctane) MIEBO is a water-free eye drop approved for treating dry eye disease and shows significant potential in reducing the evaporation rate of saline in lab tests.
- In experiments, PFHO decreased the evaporation rate by up to 88% when layered over saline, outperforming common artificial tears and demonstrating its effectiveness at both 25°C and 35°C.
- The findings suggest that PFHO could potentially replace the natural lipid layer in the tear film, providing a new option for patients suffering from dry eye disease.
$100 - $150
Hourly Rate
Addressing excessive evaporation: an unmet need in dry eye disease.
London, UK
2 hours ago
1 Received
- Dry eye disease (DED) is a prevalent condition caused by issues in the tear film, leading to symptoms like inflammation and eye injury, often due to meibomian gland dysfunction (MGD) and excessive tear evaporation.
- Current treatments for DED aim to improve tear production and reduce inflammation but have not directly addressed the evaporation issue until now.
- The FDA-approved perfluorohexyloctane (PFHO) ophthalmic solution (MIEBO™) is the first eye drop designed to combat tear evaporation, showing effectiveness in improving symptoms and surface healing in clinical trials.
$100 - $150
Hourly Rate
A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.
London, UK
2 hours ago
1 Received
- - Dry Eye Disease (DED) is a common eye condition caused by an imbalance between tear production and evaporation, often linked to meibomian gland dysfunction (MGD), leading to increased tear evaporation and ocular surface damage.
- - The FDA-approved PFHO (MIEBO™) ophthalmic solution directly targets tear evaporation without preservatives and has shown promise in stabilizing the tear film, reducing friction during blinking, and improving tear film quality in preclinical studies.
- - In phase 3 clinical trials, PFHO effectively improved DED symptoms and signs within two weeks, demonstrating lasting safety and efficacy over twelve months compared to traditional saline solutions.
$100 - $150
Hourly Rate
Perfluorohexyloctane ophthalmic solution (Miebo) for dry eye disease.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.
London, UK
2 hours ago
1 Received
- Perfluorohexyloctane ophthalmic solution (Miebo) is a unique, preservative-free treatment approved in the USA for dry eye disease (DED), particularly effective for symptoms linked to meibomian gland dysfunction (MGD).
- In clinical trials, using this solution four times daily led to significant improvements in DED symptoms compared to a standard saline solution over eight weeks.
- It was generally well-received by patients, with mild side effects, and effectiveness lasted up to 52 weeks, making it a promising new option for those suffering from excessive tear evaporation.
$100 - $150
Hourly Rate
Quintessence of currently approved and upcoming treatments for dry eye disease.
London, UK
2 hours ago
1 Received
- - Dry eye disease (DED) is a complex eye condition, and this review summarizes current and future treatment options for it by looking at research from PubMed, FDA, and other databases.
- - Current FDA-approved treatments for DED include several cyclosporine formulations, lifitegrast (XIIDRA), and various medical devices designed to improve tear production and treat meibomian gland dysfunction.
- - Numerous clinical trials are ongoing to evaluate new treatments for DED, including various novel drops and solutions, aiming to enhance symptomatic relief as well as overall management of the disease.
$100 - $150
Hourly Rate
Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study.
London, UK
2 hours ago
1 Received
- - The study aimed to evaluate the long-term safety and effectiveness of perfluorohexyloctane (PFHO) eye drops for treating dry eye disease (DED) through the KALAHARI trial, which followed a previous study called GOBI.
- - In the KALAHARI trial, 208 patients used PFHO drops for a year, with safety assessments indicating mostly mild adverse effects, while effectiveness was measured by improvements in corneal staining and dry eye scores.
- - Results showed that PFHO was safe and well-tolerated, effectively maintaining improvements in DED symptoms over the study period, including for patients who switched from saline to PFHO.
$100 - $150
Hourly Rate